Current clinical trials of metformin combined with ICB
| Title (NCT No.) | Schedule | Disease | Drug | Sponsor |
Phases |
|---|---|---|---|---|---|
| Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (NCT03048500) | Start : Jun. 2017 |
NSCLC | Metformin |
Northwestern University (BMS, NCI) | Phase 2 |
| Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer (NCT03800602) | Start: Jan. 2019 |
Colorectal |
Metformin |
Emory University (BMS) | Phase 2 |
| Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients (NCT04414540) | Start: Jul. 2020 |
HNSCC | Metformin |
UC Health (American Cancer Society) | Phase 2 |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (NCT04114136) | Start: May 2020 |
Melanoma |
Metformin |
University of Pittsburgh | Phase 2 |
| A Trial of Pembrolizumab and MetforminVersus |
Start: Dec. 2017 |
Melanoma | Metformin |
University of Pittsburgh (Merck) | Phase 1 |